4.4 Article

Validation of the Hidradenitis Suppurativa Investigator Global Assessment A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Dermatology

Sub-classification of Hidradenitis suppurativa: a cross-sectional study

Linnea Thorlacius et al.

Summary: In this study, an empirical framework for sub-classification of Hidradenitis Suppurativa (HS) patients based on the frequency of HS flares in various anatomic locations was built. Two possible subtypes, the upper type and lower type, were identified and the pattern of where lesions are located was considered as an important element in future HS sub-classification systems.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2022)

Article Dermatology

Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations

Amit Garg et al.

Summary: This study aims to provide evidence-based screening recommendations for comorbidities associated with HS. Screening recommendations were made based on the consistency and quality of existing studies, disease prevalence and magnitude of association, as well as benefits, harms, and feasibility of screening. A total of 30 comorbidities were recommended for screening in order to improve patients' quality of life and health status.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Dermatology

Patients with Hidradenitis Suppurativa Suffer from Low Health-Related Quality of Life as Measured by the Generic 15D Instrument

Mirkka J. Hirvonen et al.

Summary: The study found that HS patients have low HRQoL scores, and even mild HS has a significant impact on HRQoL. There was no correlation between HS severity measures and HRQoL scores, indicating that HS is a highly impactful disease. These findings emphasize the need for comprehensive care for patients with HS.

SKIN APPENDAGE DISORDERS (2022)

Article Dermatology

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial

Sophie Glatt et al.

Summary: In this study, bimekizumab showed clinically meaningful improvements in patients with moderate to severe HS, demonstrating greater efficacy compared to placebo. The safety profile of bimekizumab was consistent with previous studies, supporting further evaluation for HS treatment.

JAMA DERMATOLOGY (2021)

Article Dermatology

All-cause mortality among patients with hidradenitis suppurativa: A population-based cohort study in the United States

Sarah Reddy et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Article Dermatology

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

L. Thorlacius et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Article Dermatology

Increased Suicide Risk in Patients with Hidradenitis Suppurativa

Linnea Thorlacius et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)

Article Dermatology

Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis

Amit Garg et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Article Medicine, General & Internal

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Dermatology

Untitled

BRITISH JOURNAL OF DERMATOLOGY (2016)

Article Rehabilitation

A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research

Terry K. Koo et al.

JOURNAL OF CHIROPRACTIC MEDICINE (2016)

Article Medicine, General & Internal

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa A Parallel Randomized Trial

Alexa B. Kimball et al.

ANNALS OF INTERNAL MEDICINE (2012)